Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer

Abstract

Background:The increasing use of biomarkers as molecular determinants of responsiveness to conventional chemotherapy or molecular targeted therapy has raised the question of the reliability and reproducibility of their evaluation in bronchial biopsies as compared with corresponding resected surgical specimens. Results: High correlation coefficients were observed between the expression of ERCC1, hTERT and Ki-67 in the biopsies and the surgical specimens [0.83 (P < 0.0001); 0.55 (P < 0.001) and 0.64 (P < 0.0001), respectively]. On the other hand, biomarker expression in biopsy was less correlated with the expression in the whole tissue sample for the markers of signal response and transduction [0.24 (P = 0.17) and 0.29 (P = 0.09) for EGFR and phospho-Akt, respectively]. Conclusions:Our results indicate a lack of association in the expression of important biomarkers between lung biopsies and corresponding resected tumors, with discordance rates ranging between 9% and 41%. Although these results need to be further validated in larger cohorts, they indicate that the evaluation of the expression of biomarkers in bronchial biopsies can be misleading.

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

“…It has been shown that ERCC1 immunodetection faces several methodological challenges including tissue processing, rates of interobserver agreement, geographic variation in protein expression and, most importantly, lack of the standardized cutoff value in semi-quantitative IHC [39][40][41]. It has been also reported that the most frequently used antibody 8F1 has not been specific for ERCC1 [42].…”

Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer

“…Cells (1x10 4 ) were seeded in 24-well plates with 18 duplications for each cell sample: H1299 cells (parental cells as control), H1299/E cells (transfected with PCDNA3.1-ERCC1) and H1299/V cells (transfected with PCDNA3.1 vehicle only). Survival cell of each cell sample were counted in three duplications every day.…”

“…Survival of the cells were evaluated under the inverted microscope (Olympus, Tokyo, Japan). Cell number was calculated according to the formula N=(n/4)x10 4 xV. Finally, cell growth curves were drawn with cell number as the y-axis and time as the x-axis.…”

“…Current outcomes of NSCLC treatment are disappointing with dismal prognosis, and the overall 5-year survival rates remain ~15% for the past few decades (3). This is because ~55% of patients present with advanced stage at time of diagnosis (4). Platinumbased chemotherapy, is currently the mainstay of the advanced NSCLC treatment (5).…”

ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer

“…In our study, 15% of the NSCLC patients had ERCC1 positivity. In a study of 34 NSCLC cases, a 7% higher ERCC1 expression was determined and a correlation between the ERCC1 expression and tumor cell type was reported [10]. In another study, ERCC1 expression was significantly higher in metastatic tissues compared with primary tumor tissues [11].…”